ALLIANCES AND COLLABORATIONS (Tables)

6 Months Ended

Jun. 30, 2011

Sanofi [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011			2010	2011			2010
Territory covering the Americas and Australia:
	Net sales	$	2,045	$	1,828	$	4,023	$	3,706
	Discovery royalty expense		397		327		755		661
	Noncontrolling interest – pre-tax		601		500		1,174		1,020
	Profit distributions to Sanofi		(702)		(567)		(1,301)		(1,053)
Territory covering Europe and Asia:
	Equity in net income of affiliates		(65)		(88)		(151)		(188)
	Profit distributions to the Company		67		85		127		154
Other:
	Net sales in Europe comarketing countries and other		71		106		145		208
	Amortization (income)/expense – irbesartan license fee		(8)		(8)		(16)		(16)
	Supply activities and development and opt-out royalty (income)/expense		1		(9)		15		(31)
						June 30,		December 31,
Dollars in Millions						2011		2010
Investment in affiliates – territory covering Europe and Asia						$	46	$	22
Deferred income – irbesartan license fee							44		60

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Equity Method Investments Disclosure [Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2011		2010		2011		2010
Net sales	$	382	$	500	$	761	$	1,048
Gross profit		172		244		340		488
Net income		142		193		282		387

Otsuka [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
ABILIFY* net sales, including amortization of extension payment		$	706	$	633	$	1,330	$	1,250
Oncology Products collaboration fee expense			37		32		70		62
Reimbursement of operating expenses to/(from) Otsuka			(23)		(23)		(45)		(48)
Amortization (income)/expense – extension payment			17		16		33		32
Amortization (income)/expense – upfront, milestone and other
	licensing payments		2		2		4		4
						June 30,		December 31,
Dollars in Millions						2011		2010
Other assets - extension payment						$	252	$	285
Other intangible assets - upfront, milestone and other licensing payments							7		11

Lilly [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
Net sales		$	173	$	172	$	338	$	338
Distribution fees and royalty expense			71		71		140		140
Research and development expense reimbursement to Lilly – necitumumab			4		2		6		5
Amortization (income)/expense – upfront, milestone and other
	licensing payments		9		9		19		19
Japan commercialization fee (income)/expense			(6)		(11)		(15)		(19)
						June 30,		December 31,
Dollars in Millions						2011		2010
Other intangible assets – upfront, milestone and other licensing payments						$	267	$	286

Gilead [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2011		2010		2011		2010
Net sales	$	298	$	255	$	569	$	505
Equity in net loss of affiliates		3		3		8		6

AstraZeneca [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
Net sales		$	112	$	28	$	193	$	38
Profit sharing expense			52		13		90		18
Commercialization expense reimbursements to/(from) AstraZeneca			(10)		(8)		(19)		(12)
Research and development expense reimbursements to/(from) AstraZeneca			(15)		3		(29)		3
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(10)		(7)		(18)		(13)
						June 30,		December 31,
Dollars in Millions						2011		2010
Deferred income – upfront, milestone and other licensing payments						$	392	$	290

Pfizer [Member]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
Research and development reimbursements to/(from) Pfizer		$	(27)	$	(51)	$	(56)	$	(119)
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(8)		(8)		(16)		(16)
						June 30,		December 31,
Dollars in Millions						2011		2010
Deferred income – upfront, milestone and other licensing payments						$	366	$	382